Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Finerenone for Heart Failure in People Having a Heart Valve Replacement

Tests finerenone against placebo in heart failure patients having transcatheter aortic valve implantation.

Plain-language title generated from the registry record
Registry title: Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

Key facts

Where
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Tianjin, Ürümqi, Wenzhou, Wuhan, Xi’an, and Zhengzhou, ChinaSee the 61 sites
Phase
Phase 3

Where in China

  • Affiliated Beijing Chaoyang Hospital of Capital Medical UniversityBeijing, ChinaNot yet recruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical UniversityBeijing, ChinaNot yet recruiting
  • Chinese People's Liberation Army General HospitalBeijing, ChinaNot yet recruiting
  • Fuwai Hospital Chinese Academy of Medical SciencesBeijing, ChinaNot yet recruiting
  • Peking University Third HospitalBeijing, ChinaNot yet recruiting
  • The First Affiliated Hospital of Bengbu Medical UniversityBengbu, ChinaNot yet recruiting
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaNot yet recruiting
  • Xiangya Hospital of Central South UniversityChangsha, ChinaNot yet recruiting
  • Sichuan Provincial People's HospitalChengdu, ChinaNot yet recruiting
  • West China Hospital，Sichuan UniversityChengdu, ChinaNot yet recruiting
  • Army Medical Center of the People's Liberation ArmyChongqing, ChinaNot yet recruiting
  • The First Affiliated Hospital of Army Medical UniversityChongqing, ChinaNot yet recruiting
  • the second affiliated hospital of Army medical universityChongqing, ChinaNot yet recruiting
  • Fujian Medical University Union HospitalFuzhou, ChinaNot yet recruiting
  • Fuzhou University Affiliated Provincial HospitalFuzhou, ChinaNot yet recruiting
  • Guangdong Provincial People's HospitalGuangzhou, ChinaNot yet recruiting
  • Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaNot yet recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNot yet recruiting
  • The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNot yet recruiting
  • The First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaNot yet recruiting
  • The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
  • The Sir Run Run Shaw Hospital of Zhejiang University School of MedicineHangzhou, ChinaNot yet recruiting
  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaNot yet recruiting
  • Qilu Hospital of Shandong UniversityJinan, ChinaNot yet recruiting
  • Shandong Provincial Qianfoshan HospitalJinan, ChinaNot yet recruiting
  • The First Hospital of Lanzhou UniversityLanzhou, ChinaNot yet recruiting
  • Jiangsu Provincial People's HospitalNanjing, ChinaNot yet recruiting
  • Nanjing Drum Tower hospitalNanjing, ChinaNot yet recruiting
  • Nanjing First HospitalNanjing, ChinaNot yet recruiting
  • Zhongda Hospital Southeast UniversityNanjing, ChinaNot yet recruiting
  • Ningbo Medical Center Lihuili HospitalNingbo, ChinaNot yet recruiting
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaNot yet recruiting
  • QingDao Municipal HospitalQingdao, ChinaNot yet recruiting
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaNot yet recruiting
  • Renji Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaNot yet recruiting
  • Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaNot yet recruiting
  • Shanghai Chest HospitalShanghai, ChinaNot yet recruiting
  • Shanghai East HospitalShanghai, ChinaNot yet recruiting
  • The First Affiliated Hospital of Naval Medical UniversityShanghai, ChinaNot yet recruiting
  • Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, ChinaNot yet recruiting
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaNot yet recruiting
  • Liaoning Provincial People's HospitalShenyang, ChinaNot yet recruiting
  • People's Liberation Army Northern Theater Command General HospitalShenyang, ChinaNot yet recruiting
  • The First Hospital of China Medical UniversityShenyang, ChinaNot yet recruiting
  • Tianjin Chest HospitalTianjin, ChinaNot yet recruiting
  • Tianjin First Central HospitalTianjin, ChinaNot yet recruiting
  • The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaNot yet recruiting
  • Xinjiang Uygur Autonomous Region People's HospitalÜrümqi, ChinaNot yet recruiting
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNot yet recruiting
  • The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNot yet recruiting
  • Renmin Hospital of Wuhan UniversityWuhan, ChinaNot yet recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
  • Zhongnan Hospital of Wuhan UniversityWuhan, ChinaNot yet recruiting
  • The First Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaNot yet recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaNot yet recruiting
  • The Second Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaNot yet recruiting
  • Fuwai Huazhong Cardiovascular HospitalZhengzhou, ChinaNot yet recruiting
  • Henan Chest HospitalZhengzhou, ChinaNot yet recruiting
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaNot yet recruiting
  • Zhengzhou No.7 People's HospitalZhengzhou, ChinaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Trial code
NCT07575672
Record updated
16 October 2026
Original description
This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.Read full original descriptionShow less

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.

Inclusion: Age ≥ 65 years; Patients with severe aortic stenosis (aortic valve area < 1.0 cm2 or indexed area < 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI; New York Heart Association class ≥ II; Left ventricular ejection fraction ≥ 40% at baseline prior TAVI; Informed consent has been signed.

Exclusion: Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization; Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint; Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists; Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit; Estimated glomerular filtration rate < 25 ml/min/1.73 m²; Pregnant or breastfeeding patients; Life expectancy < 1 year.

ClinicalTrials.gov NCT07575672